IngredientsC13-norisoprenoid megastigmanes are a class of apocarotenoids — monocyclic terpenoids built up of thirteen carbon atoms, incorporating three methyl groups and a butyl side chain attached to a cyclohexene or cyclohexane ring with variable substitution patterns. When these aglycone (free-alcohol) cores are conjugated with one or more sugar residues via glycosidic bonds, the resulting compounds are called megastigmane glycosides.
Megastigmanes possess a C13 basic skeleton of a six-membered ring attached to a chain with four carbon atoms at the C-6 position, with methyl substitution at C-5 and dimethyl substitution at C-1 in opposite directions to each other. They occur in nature in oxygenated forms, such as alcohols, ketones, and lactones. Bicyclic megastigmane glycosides also exist in nature; both saturated megastigmanes (megastigma-ones) and unsaturated molecules containing one or more double bonds or even a triple bond are known.
Megastigmanes are a special class of secondary metabolites with unique structural features containing a C13 skeleton with different stereocenters at C-6 and C-9 and are assumed to be formed from the degradation of carotenoids by the action of carotenoid cleavage dioxygenases.
Their structural diversity has been attributed to different functionalization at the carbon atoms, as well as glycosylation pattern. These metabolites have been isolated either in free, glycosidically bound forms or as acylated derivatives from a wide diversity of the plant kingdom. The classification of megastigmanes depends on the diversity of the oxygenation positions and the biogenetic origin.
Key named subclasses and representative individual compounds include:
A comprehensive review covering the literature from the first report in 1968 through May 2022 assembled approximately 357 megastigmane glycosides with their classification, sources, biological activities, and 13C NMR data. A subsequently updated comprehensive review, focusing on classification, biosynthesis, distribution in natural sources, and chemical structures, the studied biological activities, as well as the structure-activity relationship of C13-norisoprenoid megastigmanes, covered a total of 800 such compounds up to December 2024, citing 355 references.
Megastigmanes are structurally-diverse molecules that are widely distributed in nature, occurring mainly in the plant kingdom. Megastigmanes are the most abundant norisoprenoids in nature. They have been documented across a remarkably large number of angiosperm and gymnosperm families. Representative botanical sources include:
These compounds play a crucial role in imparting wine with its characteristic variant flavors, and they are potentially important flavoring agents for the food and pharmaceutical industries. Glycosidically bound megastigmanes in grape berries are important aroma precursors; enzymatic or acid hydrolysis during fermentation liberates the volatile aglycone fragrances responsible for characteristic wine aromas.
In research and industry settings, megastigmane glycosides are typically obtained by:
Megastigmane glycosides are not used as isolated, named entities in any traditional medical system. Instead, they are components of well-documented medicinal plants used across multiple traditions. The following accounts describe traditional uses of the source plants in which megastigmane glycosides have subsequently been chemically identified.
As a Traditional Chinese Medicine, Eucommia ulmoides Oliver has been used for the treatment of various diseases since ancient times, involving lumbar pain, knee pain, osteoporosis, hepatoprotection, paralysis, intestinal haemorrhoids, vaginal bleeding, abortion, spermatorrhoea, foot fungus, and anti-aging applications. In China, E. ulmoides derivatives are mainly used to enhance immunity, improve hepatic damage, strengthen bones, and lower blood pressure. Megastigmane glycosides (eucomegastigsides A–D) were subsequently isolated from its leaves and demonstrated ACE-inhibitory properties consistent with the plant's long-standing antihypertensive reputation.
Among the various parts of Eriobotrya japonica, the leaves have gained particular attention due to their extensive use in TCM for treating chronic bronchitis, cough, nausea, and other ailments. The monograph in Chinese Herbal Medicine essentially indicates applications as an antitussive and gastric agent; Medicinal Plants in Vietnam (published under the aegis of the WHO) similarly mentions therapeutic applications as an antitussive and antispasmodic, and Chinese Materia Medica records it as an antitussive and antiemetic.
Cirsium setosum (the aboveground part of Cephalanoplos segetum Kitam) has been used as a traditional medicine against a variety of hemorrhagic diseases for thousands of years in China.
Acanthus species are used in traditional medicine mainly for diseases of the respiratory, nervous, and reproductive system, gastrointestinal and urinary tract, and skin illness. The most used species are A. montanus, A. ilicifolius, and A. ebracteatus. A. ilicifolius grows predominantly in coastal mangrove environments across South and Southeast Asia.
The quince (Cydonia oblonga Mill.) has been documented as a traditional Uighur medicine, and megastigmane glycosides have been isolated from this source as part of recent phytochemical characterization efforts. Traditional Uighur medicine utilized quince for digestive, respiratory, and inflammatory conditions.
The presence of megastigmane glycoside precursors in Vitis vinifera (grapevine) has been recognized since early studies on wine aroma chemistry. 3-Oxo-β-ionol, vomifoliol, and dehydrovomifoliol were identified in fruit from Vitis vinifera. The latter compound was mainly present free in the juice while the others existed predominantly as conjugates. Among the enzymatically liberated aglycones, 23 bound C13 norisoprenoids were identified. Five major C13 glycosides, including the β-D-glucopyranosides of vomifoliol, 4,5-dihydrovomifoliol, 3-hydroxy-5,6-epoxy-β-ionone, grasshopper ketone, and 3-oxo-megastigman-9-ol, were purified and structurally elucidated.
C13-norisoprenoid megastigmanes are biogenetically derived from the oxidative cleavage of cyclic carotenoids such as β-carotene, lutein, zeaxanthin, neoxanthin, canthaxanthin, and violaxanthin. This cleavage occurs primarily at the C-9 and C-9′ positions, generating volatile derivatives that contribute to the aroma profiles of various natural products, including wine. The degradation process is catalyzed by carotenoid cleavage dioxygenases (CCDs). The resulting C13 fragments then undergo further oxygenation (hydroxylation, ketone formation, epoxidation), and subsequently become conjugated to sugar moieties — most commonly β-D-glucopyranose, though apiofuranosyl, rhamnopyranosyl, xylopyranosyl, and disaccharide (e.g., gentiobiosyl) units are also documented — via O-glycosidic linkage at C-9 of the aglycone.
Mono-oxygenated conjugates of megastigmanes such as α-ionol, α-ionone, β-ionol, and β-ionone are rarely found in nature whereas higher-oxygenated conjugates are biosynthesized in numerous plant families.
The primary classification of megastigmane glycosides follows the oxygenation and unsaturation pattern of the aglycone ring system:
The most prevalent sugar in megastigmane glycosides is β-D-glucopyranose (as in roseoside, 3-oxo-α-ionol glucoside, and most named congeners). Disaccharide forms incorporating rhamnose, xylose, or apiose at a second position are well documented. Five megastigmane glycosides have been isolated from the seeds of Trifolium alexandrinum L., of which three are new compounds showing the presence of apiofuranosyl-(1→2)-glucopyranosyl residue as a sugar moiety. In Urena lobata, megastigmane glycosides with both rhamnopyranosyl-(1″→4′)-glucopyranoside and glucopyranosyl-(1″→6′)-glucopyranoside disaccharide chains have been identified.
The following mechanisms have been identified in cell-based (in vitro) experiments; no confirmed human mechanistic data currently exist for isolated megastigmane glycosides.
Results show that megastigmane derivatives, in particular β-damascenone and its precursors, may be responsible for the anti-inflammatory effects of Epipremnum pinnatum via inhibition of the NF-κB pathway. Pharmacological analysis demonstrated that β-damascenone inhibits LPS-stimulated induction of mRNAs encoding for proinflammatory cytokines and leukocyte adhesion molecules, such as TNF-α, IL-1β, IL-8, COX-2, E-selectin, ICAM-1, and VCAM-1 in HUVECtert and THP-1 cells. Using a luciferase reporter construct, it was shown that β-damascenone inhibits NF-κB-dependent transcription, and researchers hypothesize that inhibition of NF-κB may represent one of the mechanisms underlying the in vitro anti-inflammatory activity of Epipremnum pinnatum extracts.
It is most likely that the α,β-unsaturated carbonyl moiety of β-damascenone is responsible for this effect. Since α,β-unsaturated carbonyl moieties interact with many signal-transduction proteins, it needs to be clarified whether β-damascenone expresses its effects only by targeting proteins within the NF-κB and Nrf2 signaling cascade, or whether it also affects other signaling pathways.
A megastigmane isolated from Urena lobata exhibited inhibition of nitric oxide production in LPS-stimulated RAW264.7 macrophage cells with an IC₅₀ value of 53.7 ± 1.0 μM (positive control dexamethasone: IC₅₀ = 16.6 ± 0.8 μM). Inhibition of nitric oxide (NO), TNF-α, and IL-6 production in LPS-stimulated RAW 264.7 cells has also been demonstrated for megastigmane derivatives from Corispermum mongolicum and Docynia indica.
The anti-hypertensive effect of megastigmane glycosides from Eucommia ulmoides was investigated in vitro based on the inhibition of Angiotensin Converting Enzyme (ACE) using HPLC, and the results showed that several isolates had moderate inhibitory effects on ACE in vitro compared with captopril. Four new megastigmane glycosides (eucomegastigsides A–D) from E. ulmoides leaves showed inhibition ratios of 24.6 ± 0.5%, 29.1 ± 0.6%, 31.2 ± 0.2%, and 29.7 ± 0.4%, respectively, at the concentration of 240 μg/mL against ACE, compared with captopril (98.0 ± 0.1% at 240 μg/mL), showing moderate activities.
Neuroprotective activity of megastigmane glycosides was assessed in an Hâ‚‚Oâ‚‚-induced PC12 cell model, and several compounds from Heterosmilax yunnanensis exhibited good neuroprotective activity compared to the positive control edaravone. The proposed mechanism involves attenuation of oxidative stress-induced neuronal cell death.
A number of reports show megastigmane compounds demonstrating activity against DPPH radical scavenging and exhibiting hepatoprotective activities.
Important note on evidence level: Virtually all scientific evidence for the biological activities of megastigmane glycosides originates from in vitro (cell-based) and limited in vivo (animal) experiments. As of the literature reviewed through 2025, there are no published randomized controlled trials (RCTs) specifically testing isolated megastigmane glycosides in human populations. Clinical human evidence is restricted to a single study of a complex Eucommia ulmoides leaf extract (containing multiple compound classes, of which megastigmane glycosides are one component). All activity data below should therefore be understood as preliminary and preclinical unless otherwise stated.
Evidence level: Preliminary; in vitro cell models only (with one study in LPS-stimulated macrophages and endothelial cells).
Bioactivity-guided fractionation of Epipremnum pinnatum extracts using PTGS2 (COX-2) mRNA as a readout resulted in the isolation of two C13 megastigmane glycosides (gusanlungionoside C and citroside A). Further analysis identified six additional megastigmane glycosides and aglycone forms including β-damascenone, megastigmatrienone, 3-hydroxy-β-damascenone, and 3-oxo-7,8-dihydro-α-ionol. Pharmacological analysis demonstrated that β-damascenone inhibits LPS-stimulated induction of mRNAs for TNF-α, IL-1β, IL-8, COX-2, E-selectin, ICAM-1, and VCAM-1 in HUVECtert and THP-1 cells.
The anti-inflammatory activities of megastigmane derivatives from Docynia indica were evaluated by examining the secretion of inflammatory markers (NO, TNF-α, and IL-6) by LPS-stimulated RAW 264.7 cells; compounds 1–2, 4, and 5 exhibited anti-inflammatory activities, and compound 2 was found to possess better inhibitory activity than the other compounds tested.
As shown in previous studies, megastigmane derivatives from Corispermum mongolicum possess anti-inflammatory activities.
A megastigmane glycosylsulfate from Salvadora persica fractionation experiments also showed moderate IL-8 and TNF-α release inhibition in human cell assays. Across all anti-inflammatory work, the evidence is limited to in vitro cell models; dose-response relationships and selectivity profiling are incomplete, and translation to in vivo inflammation models, let alone human studies, has not been established for isolated megastigmane glycosides.
Evidence level: Preliminary; in vitro cell models, and limited in vivo rodent experiments reported in context of source plant reviews. Anti-melanogenic and hepatoprotective activities have been characterized as the most promising bioactivities of the class.
The biological activities of megastigmane glycosides have been reported, including anti-melanogenic, anti-inflammatory, neuroprotective, antioxidant, antitumor, antimicrobial, and hepatoprotective activities. Anti-melanogenic and hepatoprotective activities are the most promising reported bioactivities.
Most megastigmane compounds have been isolated from plant sources such as Urena lobata, Epipremnum pinnatum, Eucommia ulmoides, and Paronychia arabica. These substances have been reported to show diverse biological properties including anti-inflammatory, antihypertensive, anticancer, radical-scavenging (DPPH), and hepatoprotective activities.
Ninomiya et al. (2007) are frequently cited in the literature as demonstrating hepatoprotective activity for megastigmane glycosides, though direct clinical translation of these findings is not yet available.
Evidence level: Preliminary; largely in vitro DPPH or similar radical-scavenging assays.
Several reports show megastigmane compounds demonstrating potential activity against radical scavenging (DPPH) and hepatoprotective activities. Antioxidant effects have been demonstrated in multiple isolated compound studies; however, the clinical significance of these findings has not been established in human studies. The role of the free hydroxyl groups on the C13 skeleton in radical donation is postulated as the primary mechanism, though detailed structure-activity relationship studies remain incomplete. A 2022 study specifically investigated anti-inflammatory and antioxidant effects of (6S,9R)-vomifoliol — one of the most widespread megastigmane aglycones — in human immune cell models, providing cell-based evidence of activity in ex vivo human leukocytes.
Evidence level: Preliminary; in vitro cell-based assays; identified as among the most promising bioactivities of the class.
Anti-melanogenic activity — meaning inhibition of melanin biosynthesis — has been reported for several megastigmane glycosides, particularly those from marine and terrestrial plant sources. Lee et al. (2015) are cited in comprehensive reviews as demonstrating anti-melanogenic effects. The mechanism is believed to involve inhibition of tyrosinase activity or downstream signaling in melanocyte cell lines, but published mechanistic details for specific glycoside structures remain fragmented in the peer-reviewed literature. No human clinical trials of megastigmane glycosides for skin pigmentation have been published.
Evidence level: Preliminary; in vitro neuronal cell models only.
The neuroprotective activity of megastigmane glycosides from Heterosmilax yunnanensis was assessed in an H₂O₂-induced PC12 cell model; compounds 3 and 6–10 exhibited good neuroprotective activity compared to the positive control edaravone. PC12 cells are a widely used but highly simplified model; results from such assays are considered very preliminary and cannot be extrapolated to human neurodegeneration without further in vivo and clinical validation.
Evidence level: In vitro enzyme assay (ACE inhibition); one human observational/interventional study at the level of complex plant extract (not isolated glycosides).
Moderate ACE-inhibitory activity was observed for five megastigmane glycosides (eucomegastigsides A–D and oliasalacioside B1) isolated from Eucommia ulmoides.
The hypotensive effects and safety of beverages containing Eucommia leaf glycosides were examined in a randomized double-blind, placebo-controlled, parallel group study in high normotensive and mild hypertensive adult male and female subjects. Test or placebo meals were given once per day for 12 weeks. The results revealed that systolic blood pressure was significantly reduced after 4 weeks of intake in the treatment group. Between the two groups, there was a significant difference in SBP at 8, 10, and 12 weeks and in DBP at 10 and 12 weeks. No significant abnormal changes were observed in blood examination, urinalysis, and physical examination. Additionally, clinically relevant adverse effects such as digestive tract symptoms, dry cough, or allergic phenomena were not observed in association with test-meal intake. This clinical study, however, used a complex extract containing chlorogenic acid, geniposidic acid, aucubin, and multiple glycoside classes; it cannot be attributed specifically to megastigmane glycosides alone.
Evidence level: Preliminary; in vitro cytotoxicity cell line assays only.
Cytotoxic activity has been reported for certain megastigmane glycosides (Fan et al., 2017), alongside antibacterial, antiviral, neuroprotective, antioxidant, hepatoprotective, anti-inflammatory, anti-melanogenic, and anti-allergic activities. The literature has highlighted several compounds that need further development and optimization for drug discovery programs of hepatoprotective, anti-inflammatory, antioxidant, cytotoxic, anti-melanogenic, and cholesterol and triglycerides metabolism. No human cancer treatment data exist for isolated megastigmane glycosides.
Evidence level: Preliminary; in vitro microbial assays only.
Antibacterial activity of megastigmane glycosides has been reported (Bao et al., 2017, as cited in comprehensive reviews). Megastigmane compounds isolated from Euonymus fortunei were evaluated for antimicrobial activities against Ureaplasma urealyticum in vitro, but all tested compounds showed no useful activities against this organism. This highlights that antimicrobial activity is compound- and organism-specific rather than a general property of the class.
Evidence level: Very preliminary; single cited in vitro study (Goda et al., 1999).
Anti-allergic activity has been listed in comprehensive reviews of the class, citing work by Goda et al. (1999), but the specific mechanistic basis (e.g., mast cell stabilization, histamine inhibition) for isolated megastigmane glycosides has not been elaborated in accessible primary literature reviewed here.
Eriobotrya japonica is valued not only for its fruit but also for its seeds and flowers, which are used in traditional medicine for their potential analgesic, anti-tumor, and respiratory health benefits. 164 compounds, including triterpenes, flavonoids, sesquiterpene glycosides, megastigmane derivatives, phenylpropanoids, and organic acids, have been identified from E. japonica leaves, in addition to 169 volatile oils. More than half of these compounds have not yet been reported to have pharmacological activities. Triterpenes and flavonoids are the most important bioactive compounds responsible for pharmacological activities such as antidiabetic, anti-inflammatory, and antitumor activities. This illustrates that, even in well-studied medicinal plants, the relative pharmacological contribution of megastigmane glycosides versus other compound classes remains incompletely defined.
Based on available in vitro and limited in vivo evidence, megastigmane glycosides have been associated with the following body systems:
No standardized therapeutic dose of isolated megastigmane glycosides has been established in any human clinical trial. The following data reflect dosages reported in laboratory experiments or complex extract studies:
Megastigmane glycosides are consumed in small amounts as part of normal dietary intake via fruits, vegetables, wines, and herbal teas containing their source plants. Quantitative dietary intake estimates for human populations have not been systematically published in peer-reviewed literature.
No dedicated clinical toxicology studies on isolated megastigmane glycosides as a class have been published. Safety data are limited to observations made in the context of source plant research:
The classification of plants based on their chemical constituents is a powerful weapon for plant taxonomists. A major review describes the distribution of megastigmane glycosides in different plant species and families and discusses the chemotaxonomic significance of these compounds. It has been reported that the megastigmane glycoside (6R,9R)-3-oxo-α-ionol 9-β-D-glucopyranoside was isolated for the first time from the genus Persea, and this could be a potential chemotaxonomic marker for that genus. Similarly, the presence of specific megastigmane glucosides plays an important role in the authentication of Vitis quinquangularis.
The literature has highlighted several megastigmane glycoside compounds that need further development and optimization for drug discovery programs of hepatoprotective, anti-inflammatory, antioxidant, cytotoxic, anti-melanogenic, and cholesterol and triglycerides metabolism.
Megastigmane derivatives and their glycosides are widely distributed in the plant kingdom and reported to possess wide-ranging biological properties, making them active constituents of several plants and promising candidates for drug development.
Key gaps include: (1) absence of human pharmacokinetic data for any isolated megastigmane glycoside; (2) no RCTs testing isolated compounds in any disease indication; (3) incomplete structure-activity relationship data linking specific substitution patterns to specific bioactivities; (4) unresolved questions about bioavailability following oral ingestion and the relative activity of parent glycosides versus hydrolyzed aglycones in vivo; and (5) the need for dedicated safety pharmacology and toxicology studies of the most active individual compounds before clinical development can proceed.
Health conditions that Megastigmane glycosides may help support.
Body systems that Megastigmane glycosides may help support.
Go back